Skip to main content
SpringerLink
Log in

Noninvasive Breast Cancer

  • Chapter
  • First Online:
Surgical Oncology

  • 3501 Accesses

Abstract

Noninvasive breast cancer includes ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS). Phyllodes tumors are rare stromal tumors whose histology and behavior vary from benign to malignant. In both DCIS and LCIS, abnormal cells are present within the lining of the duct or lobule but have not invaded through the basement membrane. These lesions have different behaviors and different demographic profiles. Neither DCIS nor LCIS has potential for metastases. The majority of in situ breast cancers are DCIS. DCIS represents a premalignant marker for invasive breast cancer risk in the ipsilateral breast, whereas LCIS confers an increased risk for the development of invasive breast cancer in both breasts. The majority of DCIS are found radiographically, while the majority of LCIS are found incidentally on biopsy. Immunohistochemical staining with E-cadherin allows differentiation of DCIS and LCIS. Identification of histologic subtypes of DCIS allows for prognostication and aids management decisions. The treatment and prevention goals are more aggressive for DCIS compared to LCIS. When possible, breast conservation with wide excision to negative margins is generally followed by postoperative radiation. Unlike DCIS, clear margins (except for the pleomorphic subtype) are not required for excision of LCIS, and ipsilateral mastectomy and radiation are not indicated. Women with estrogen receptor-positive DCIS benefit from adjuvant endocrine therapy, and trials suggest that women with LCIS may benefit from tamoxifen or raloxifene. Phyllodes tumors are mostly benign lesions with malignant potential. Surgical treatment for the majority of phyllodes tumors is wide local excision. Adjuvant radiotherapy may be beneficial for malignant and borderline phyllodes tumors treated with breast-conserving surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

DCIS:

Ductal carcinoma in situ

LCIS:

Lobular carcinoma in situ

SEER:

Surveillance, epidemiology, and end results

ADH:

Atypical ductal hyperplasia

ER:

Estrogen receptor

PR:

Progesterone receptor

BCT:

Breast-conserving therapy

NSABP:

National surgical adjuvant breast & bowel project

EORTC:

European Organization for Research and Treatment of Cancer

ECOG:

Eastern Cooperative Oncology Group

SLNB:

Sentinel lymph node biopsy

NCCN:

National Comprehensive Cancer Network

MRI:

Magnetic resonance imaging

STAR:

Study of tamoxifen and raloxifen

PLCIS:

Pleomorphic lobular carcinoma in situ

References

  1. American Cancer Society. Breast cancer facts & figures 2011–2012. Atlanta: American Cancer Society, Inc. 2011.

    Google Scholar 

  2. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22–24, 2009. J Natl Cancer Inst. 2010;102(3):161–69.

    Google Scholar 

  3. Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89:76.

    Article  PubMed  CAS  Google Scholar 

  4. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78:7.

    Article  PubMed  CAS  Google Scholar 

  5. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160(7):953.

    Article  PubMed  CAS  Google Scholar 

  6. Rosen PP. Fibroepithelial neoplasms. In: Rosen PP, editor. Rosen’s breast pathology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 187–229.

    Google Scholar 

  7. Esserman LJ, Thompson Jr IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013;310(8):797–8.

    Article  PubMed  CAS  Google Scholar 

  8. Patani N, Khaled Y, Al Reefy S, Mokbel K. Ductal carcinoma in-situ: an update for clinical practice. Surg Oncol. 2011;20(1):e23–31.

    Article  PubMed  Google Scholar 

  9. Giuliano AE, Mabry H. Ductal and lobular carcinoma in situ of the breast. In: Cameron JL, editor. Current surgical therapy. Philadelphia: Mosby Elsevier; 2009.

    Google Scholar 

  10. Dershaw DD, Abramson A, Cha I, et al. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology. 1989;170:411.

    Article  PubMed  CAS  Google Scholar 

  11. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186:337.

    Article  PubMed  Google Scholar 

  12. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400.

    Article  PubMed  CAS  Google Scholar 

  13. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Julien JP, Biijker N, Fentiman IS, et al. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853 – EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528–33.

    Article  PubMed  CAS  Google Scholar 

  15. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455.

    Article  PubMed  CAS  Google Scholar 

  16. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.

    Article  PubMed  Google Scholar 

  17. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–52.

    Article  PubMed  Google Scholar 

  18. Boland GP, Chan KC, Kox WF, et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conservation surgery. Br J Surg. 2003;90(4):426.

    Article  PubMed  CAS  Google Scholar 

  19. MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer. 2007;1109120:2648.

    Article  Google Scholar 

  20. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319–24. Epub 2009 Oct 13.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30(6):600–7. Epub 2012 Jan 17.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res. 2011;71(24):108s.

    Google Scholar 

  23. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353:1993.

    Article  PubMed  CAS  Google Scholar 

  25. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res. 2002;75(3):259–68.

    Article  Google Scholar 

  26. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expressio n of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115(1):85–9.

    Article  PubMed  CAS  Google Scholar 

  27. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534.

    Article  PubMed  Google Scholar 

  28. Page DL, Kidd Jr TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232.

    Article  PubMed  CAS  Google Scholar 

  29. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and typical lobular hyperplasia of the breast-A review. Eur J Surg Oncol. 2011;37:279–89.

    Article  PubMed  CAS  Google Scholar 

  30. National Comprehensive Cancer Network (NCCN) guidelines for DFSP. Available at: www.nccn.org. Accessed 1 Sept 2012

  31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652.

    Article  PubMed  CAS  Google Scholar 

  32. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727.

    Article  PubMed  CAS  Google Scholar 

  33. Khosravi-Shahi P. Management of non-metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 2011;20:143–8.

    Article  Google Scholar 

  34. Hawkins RE, Schofield JB, Fisher C, et al. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer. 1992;69(1):141–7.

    Article  PubMed  CAS  Google Scholar 

  35. Chua CL, Thomas A, Ng BK. Cystosarcoma phyllodes: a review of surgical options. Surgery. 1989;105:141–7.

    PubMed  CAS  Google Scholar 

  36. Ward RM, Evans HL. Cystosarcoma phyllodes a clinicopathologic study of 26 cases. Cancer. 1986;58:2282–9.

    Article  PubMed  CAS  Google Scholar 

  37. Komenaka IK, El-Tamer M, Pile-Spellman E, et al. Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch Surg. 2003;138:987–90.

    Article  PubMed  Google Scholar 

  38. Barnhart GR, DeBlois GG, Kay S, Neifeld JP. Management of Cystosarcoma: a reassessment. Breast Dis Breast. 1985;11(2):17–23.

    Google Scholar 

  39. Pandey M, Mathew A, Kattoor J, et al. Malignant phyllodes. Breast J. 2001;7:411–6.

    Article  PubMed  CAS  Google Scholar 

  40. Barth RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes. Ann Surg Oncol. 2009;16:2288–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Geisinger Health System, 100 North Academy Ave., Danville, PA, 17822, USA

    Tania K. Arora M.D.

  2. Department of Surgery, Virginia Commonwealth University, 980011, Richmond, VA, 23298-0011, USA

    Harry D. Bear M.D., Ph.D.

Authors
  1. Tania K. Arora M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry D. Bear M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harry D. Bear M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Arora, T.K., Bear, H.D. (2015). Noninvasive Breast Cancer. In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation